Clover Corporation Limited (ASX:CLV)
Australia · Delayed Price · Currency is AUD | Market Cap | 174.38M +52.4% |
| Revenue (ttm) | 97.41M +13.3% |
| Net Income | 10.46M +49.1% |
| EPS | 0.06 +49.0% |
| Shares Out | 166.07M |
| PE Ratio | 16.77 |
| Forward PE | 12.60 |
| Dividend | 0.03 (2.38%) |
| Ex-Dividend Date | Oct 20, 2026 |
| Volume | 106,655 |
| Open | 1.010 |
| Previous Close | 1.020 |
| Day's Range | 1.010 - 1.050 |
| 52-Week Range | 0.655 - 1.165 |
| Beta | -0.34 |
| Analysts | Buy |
| Price Target | 1.32 (+25.24%) |
| Earnings Date | Sep 23, 2026 |
About Clover Corporation
Clover Corporation Limited engages in the production, refining, and sale of natural oils and encapsulated powders in Australia, New Zealand, Asia, Europe, the Middle East, and the Americas. It supplies refined Omega 3 oils and various encapsulated ingredients for infant formula, nutraceuticals, pharmaceuticals, and sports nutrition markets. The company offers Nu-Mega’s Driphorm microencapsulated powders, which enables the addition of Hi-DHA tuna and/or algal oils to products. It offers its products in dry powder form. Clover Corporation Limited... [Read more]
Financial Performance
In fiscal year 2026, Clover Corporation's revenue was 97.41 million, an increase of 13.26% compared to the previous year's 86.00 million. Earnings were 10.46 million, an increase of 49.08%.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CLV stock is "Buy." The 12-month stock price target is $1.32, which is an increase of 25.24% from the latest price.
News
Clover Corporation Earnings Call Transcript: H2 2026
FY 2026 revenue reached AUD 97.4m, with higher gross margin, EBITDA and NPAT; ARA demand and vertical integration were key growth drivers. FY 2027 H1 revenue is expected to exceed the prior period, while CholineXcel scale-up and U.S. market entry require investment.
Clover Corporation Earnings release: H2 2026
Clover Corporation released its H2 2026 earnings on September 22, 2026, summarizing the period's financial results.
Clover Corporation Slides: H2 2026
Clover Corporation has posted slides in relation to its H2 2026 quarterly earnings report, which was published on September 22, 2026.
Clover Corporation Annual report: H2 2026
Clover Corporation has published its H2 2026 annual report on September 22, 2026.
Clover Corporation Earnings Call Transcript: H1 2026
Record half-year revenue and margin growth driven by new products, diversified customer base, and operational improvements. Strong outlook for the full year with guidance of AUD 92–96 million, supported by robust demand and expanded distribution.
Clover Corporation Quarterly report: H1 2026
Clover Corporation has published its H1 2026 quarterly earnings report on March 23, 2026.
Clover Corporation Slides: H1 2026
Clover Corporation has posted slides in relation to its H1 2026 quarterly earnings report, which was published on March 23, 2026.
Clover Corporation Earnings release: H1 2026
Clover Corporation released its H1 2026 earnings on March 23, 2026, summarizing the period's financial results.
Clover Corporation Transcript: AGM 2025
The AGM highlighted strong revenue growth, reduced debt, and a higher dividend, with strategic focus on product innovation, market diversification, and expansion into nutraceuticals and seniors' nutrition. Board transitions and governance updates were addressed, and all resolutions were put to a poll.
Clover Corporation Slides: FY 2025
Clover Corporation has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 17, 2025.